- $46.16m
- -$41.88m
- $0.10m
Annual balance sheet for iBio, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 33.5 | 4.3 | 14.2 | 8.58 | 88 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 6.1 | 0.204 | 0.713 | 0.105 | 1.1 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 45.1 | 26.3 | 15.7 | 9.72 | 92.2 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 41.8 | 7.55 | 6.37 | 5.28 | 4.75 |
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 99.4 | 41.2 | 28.7 | 23.2 | 99.1 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 30.4 | 21.6 | 3.84 | 6.11 | 11.7 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 35.9 | 25.8 | 7.41 | 8.3 | 13.4 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 63.5 | 15.4 | 21.3 | 14.9 | 85.7 |
| Total Liabilities & Shareholders' Equity | 99.4 | 41.2 | 28.7 | 23.2 | 99.1 |
| Total Common Shares Outstanding |